PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634498
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634498
HER2 positive metastatic gastric cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035
The proto-oncogene HER2 is encoded by ERBB2, which is located on chromosome 17. It is a member of the HER family and is composed of four receptor tyrosine kinases bound to the plasma membrane that transmit extracellular signals to initiate cellular signaling pathways through mitogen-activated protein kinase, phosphoinositide 3-kinase, phospholipase C, protein kinase C, and signal transducer and activator of transcription. Gastric cancer (GC), one of the most fatal neoplasms in gastrointestinal oncology, gives patients little hope for a full recovery. When it is found to be in an advanced stage, which is defined as an unresectable locoregional or metastatic disease, the prognosis for gastric cancer is very poor, with a 5-year survival rate of no more than 20%.
Description
On chromosome 17, ERBB2, which encodes the proto-oncogene HER2, is found. It belongs to the HER family and is made up of four receptor tyrosine kinases that are bound to the plasma membrane and transmit extracellular signals to start cellular signaling pathways for mitogen-activated protein kinase, phosphoinositide 3-kinase, phospholipase C, protein kinase C, and signal transducer and activator of transcription. Patients with gastric cancer (GC), one of the most lethal neoplasms in gastrointestinal oncology, have slim chances of making a full recovery. Although those with metastatic disease have a worse prognosis, cancer-related mortality ultimately results from this. The human epidermal growth factor receptor 2 (HER2), which is overexpressed or amplified in 6 to 36% of GC patients, is a key target of new mGC therapy methods.
HER2 positive metastatic gastric cancer (Epidemiology)
In the US, stomach cancer accounts for 10% of all new cancer cases; in 2018, it was anticipated that there would be 26,240 new cases and 10,800 fatalities. Though incidence and mortality have been on the decline, the expense of treating stomach cancer has increased significantly, as has the strain it places on healthcare systems. Gastric cancer has a very poor prognosis when it is discovered to be in an advanced stage, which is defined as an unresectable locoregional or metastatic disease. Only 20% of patients will survive for five years after diagnosis.
HER2 positive metastatic gastric cancer -Current Market Size & Forecast Trends
The market for HER2-positive gastric cancer is projected to experience steady growth, with an estimated value of approximately USD 1.26 billion in 2023, expected to reach around USD 1.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.5% during this period. This growth is driven by increasing incidence rates of gastric cancer, advancements in targeted therapies, and the introduction of new drugs such as Enhertu, which specifically targets HER2-positive tumors. The rising awareness of gastric cancer symptoms and the development of more effective treatment options are also expected to contribute to market expansion. North America is anticipated to dominate the market due to its established healthcare infrastructure and significant investments in research and development, while regions like Asia-Pacific are expected to see increased demand as healthcare access improves. Overall, the HER2-positive gastric cancer market is well-positioned for growth through 2035, supported by ongoing innovations and a focus on improving patient outcomes.
After the ToGA trial's success, a number of anti-HER2 drugs were examined, but until the Keynote-811 trial, which added pembrolizumab to trastuzumab in combination with chemotherapy, none produced a clinical improvement that was significant enough to be taken into consideration as a viable alternative for HER2-targeted therapy in advanced GC. First time in the 11 years since ToGA that a combination has shown a survival advantage. Patients who had already received more than two lines of therapy were also found to benefit from the use of trastuzumab deruxtecan (T-DXd). The best treatment for GC, that is HER-2 positive, still needs to be developed despite these promising options.
Report Highlights
HER2 positive metastatic gastric cancer - Current Market Trends
HER2 positive metastatic gastric cancer - Current & Forecasted Cases across the G8 Countries
HER2 positive metastatic gastric cancer - Market Opportunities and Sales Potential for Agents
HER2 positive metastatic gastric cancer - Patient-based Market Forecast to 2035
HER2 positive metastatic gastric cancer - Untapped Business Opportunities
HER2 positive metastatic gastric cancer - Product Positioning Vis-a-vis Competitors' Products
HER2 positive metastatic gastric cancer - KOLs Insight
Table of Content
1. HER2 positive metastatic gastric cancer Background
- 1.1. HER2 positive metastatic gastric cancer Definition
- 1.2. Signs and Symptoms
- 1.3. Pathogenesis
- 1.4. Clinical Manifestation
- 1.5. HER2 positive metastatic gastric cancer biomarkers
- 1.6. Diagnosis
2. Epidemiology Estimated and Forecast to 2035
- 2.1. Epidemiology Research Method & Data Sources Used
- 2.2. United States
- 2.2.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.2.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.3. United Kingdom
- 2.3.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.3.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.4. Spain
- 2.4.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.4.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.5. Germany
- 2.5.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.5.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.6. France
- 2.6.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.6.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.7. Italy
- 2.7.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.7.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.8. Japan
- 2.8.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.8.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.9. China
- 2.9.1. Incident Cases of HER2 positive metastatic gastric cancer
- 2.9.2. Diagnosed and treatable cases of HER2 positive metastatic gastric cancer by line of therapies (LOT)
- 2.10. Current Unmet Needs in HER2 positive metastatic gastric cancer
3. Current Treatment Paradigm
- 3.1. Treatment/Prevention guidelines
- 3.2. Regulatory Approvals/Indication and Current Benchmarks
4. KOLs Insight (US, EU, JP, CH)
- 4.1. Unmet Needs
- 4.2. Analysis of the progress in terms of approvals & current pipeline
- 4.3. Impact on the treatment algorithm and product positioning
- 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
- 4.5. Physicians Preferences for the new pharmacological agents
5. What's New in 2024/2025
6. Future Treatment Paradigm
- 6.1. HER2 positive metastatic gastric cancer Competitor Landscape and Approvals Anticipated
- 6.2. Future Treatment Algorithms and Competitor Positioning
- 6.3. Key Data Summary for Emerging Treatment
7. Late Phase Therapies Strategic Considerations in HER2 positive metastatic gastric cancer
8. Total Market Forecast
- 8.1. Key Summary Findings
- 8.1.1. G8 total Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 8.1.2. G8 total Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
9. Market Forecast by Country
- 9.1. United States
- 9.1.1. United States Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.1.2. United States Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.2. Germany
- 9.2.1. Germany Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.2.2. Germany Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.3. France
- 9.3.1. France Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.3.2. France Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.4. Italy
- 9.4.1. Italy Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.4.2. Italy Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.5. Spain
- 9.5.1. Spain Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.5.2. Spain Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.6. United Kingdom
- 9.6.1. United Kingdom Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.6.2. United Kingdom Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.7. Japan
- 9.7.1. Japan Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.7.2. Japan Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
- 9.8. China
- 9.8.1. China Market for HER2 positive metastatic gastric cancer 2022-2035 (USD Million)
- 9.8.2. China Market for HER2 positive metastatic gastric cancer by Therapies 2022-2035 (USD Million)
10. Market Drivers and Barriers
